{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:47:04Z","timestamp":1776127624214,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HL51971"],"award-info":[{"award-number":["P01HL51971"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM104357"],"award-info":[{"award-number":["P20GM104357"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL116774"],"award-info":[{"award-number":["R00HL116774"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clinthera.2014.09.023","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T19:20:07Z","timestamp":1416511207000},"page":"1873-1881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["New Approaches for Managing Preeclampsia: Clues From Clinical and Basic Research"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct00116272","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00141310","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00347867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01107782","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct018086059","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric M.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.09.023_bib1","first-page":"1122","article-title":"Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet gynecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib2","doi-asserted-by":"crossref","first-page":"e005145","DOI":"10.1136\/bmjopen-2014-005145","article-title":"Termination of pregnancy for maternal indications at the limits of fetal viability: A retrospective cohort study in the Dutch tertiary care centres","volume":"4","author":"van Eerden","year":"2014","journal-title":"BMJ open"},{"key":"10.1016\/j.clinthera.2014.09.023_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/jhh.2009.45","article-title":"Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach","volume":"24","author":"Poon","year":"2010","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.023_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/HJH.0b013e328345500c","article-title":"Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study","volume":"29","author":"Gaillard","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.023_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/bmj.38380.674340.E0","article-title":"Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies","volume":"330","author":"Duckitt","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2014.09.023_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.03761106","article-title":"Pathophysiology of the clinical manifestations of preeclampsia","volume":"2","author":"Hladunewich","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1479-828X.1995.tb01879.x","article-title":"An instructive case of abdominal pregnancy","volume":"35","author":"Shembrey","year":"1995","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bpobgyn.2010.10.009","article-title":"Deep placentation","volume":"25","author":"Pijnenborg","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib9","first-page":"177","article-title":"The role of the spiral arteries in the pathogenesis of preeclampsia","volume":"1","author":"Brosens","year":"1972","journal-title":"Obstet Gynecol Annu"},{"key":"10.1016\/j.clinthera.2014.09.023_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2014.09.023_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.09.023_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1582-4934.2009.00941.x","article-title":"A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use","volume":"14","author":"Wu","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clinthera.2014.09.023_bib13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/01.RES.0000147365.86159.f5","article-title":"Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia","volume":"95","author":"Ahmad","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2014.09.023_bib14","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1210\/en.2004-0533","article-title":"Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia","volume":"145","author":"Nagamatsu","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2014.09.023_bib15","doi-asserted-by":"crossref","first-page":"R1629","DOI":"10.1152\/ajpregu.00330.2010","article-title":"Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants","volume":"299","author":"George","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/HYPERTENSIONAHA.109.141473","article-title":"Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats","volume":"55","author":"Murphy","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib17","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00820.x","article-title":"Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model","volume":"14","author":"Bergmann","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clinthera.2014.09.023_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/HYPERTENSIONAHA.109.141937","article-title":"Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension","volume":"55","author":"Gilbert","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib19","doi-asserted-by":"crossref","first-page":"R1495","DOI":"10.1152\/ajpregu.00325.2011","article-title":"Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats","volume":"301","author":"George","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/HYPERTENSIONAHA.107.096594","article-title":"Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression","volume":"50","author":"Gilbert","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/HYPERTENSIONAHA.111.169755","article-title":"Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension","volume":"57","author":"George","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/HYPERTENSIONAHA.107.092098","article-title":"Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia","volume":"50","author":"Li","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/HYPERTENSIONAHA.109.134668","article-title":"Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice","volume":"54","author":"Suzuki","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1172\/JCI4106","article-title":"Patients with preeclampsia develop agonistic autoantibodies against the angiotensin at1 receptor","volume":"103","author":"Wallukat","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.09.023_bib25","article-title":"Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice","author":"Siddiqui","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.023_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.109.137935","article-title":"Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-aa) in pregnant rats: Role of endothelin-1","volume":"54","author":"LaMarca","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadhani","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.09.023_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2002.126179","article-title":"A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans","volume":"72","author":"Eppler","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.09.023_bib29","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1242\/dev.127.18.3941","article-title":"Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression","volume":"127","author":"Miquerol","year":"2000","journal-title":"Development"},{"key":"10.1016\/j.clinthera.2014.09.023_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/mend.13.4.0265","article-title":"Alternative splicing of vascular endothelial growth factor (VEGF)-r1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity","volume":"13","author":"He","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib31","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S0002-9378(12)91845-1","article-title":"Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia","volume":"170","author":"Kupferminc","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1471-0528.1995.tb09020.x","article-title":"Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia","volume":"102","author":"Vince","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/HYPERTENSIONAHA.108.120881","article-title":"Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: Effect of tumor necrosis factor-alpha blockade","volume":"52","author":"LaMarca","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.HYP.0000238442.33463.94","article-title":"Hypertension produced by reductions in uterine perfusion in the pregnant rat: Role of interleukin 6","volume":"48","author":"Gadonski","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0895-7061(01)02255-5","article-title":"Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression","volume":"15","author":"Alexander","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.023_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/01.HYP.0000169152.59854.36","article-title":"Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats","volume":"46","author":"LaMarca","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/HJH.0b013e3283468392","article-title":"Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: Effect of tumor necrosis factor blockade","volume":"29","author":"Gutkowska","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.023_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.2012.630388","article-title":"Update upon efficacy and safety of TNF-alpha inhibitors","volume":"11","author":"Murdaca","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2014.09.023_bib39","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v19.i17.2591","article-title":"Tumor necrosis factor-alpha inhibitor therapy and fetal risk: A systematic literature review","volume":"19","author":"Marchioni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib40","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.108.120576","article-title":"Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats","volume":"52","author":"LaMarca","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.reprotox.2009.02.004","article-title":"Angiotensin II receptor blockers in pregnancy: A report of five cases","volume":"28","author":"Gersak","year":"2009","journal-title":"Reproductive toxicology"},{"key":"10.1016\/j.clinthera.2014.09.023_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdra.20102","article-title":"Angiotensin II receptor antagonist treatment during pregnancy","volume":"73","author":"Alwan","year":"2005","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nm.1856","article-title":"Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice","volume":"14","author":"Zhou","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2014.09.023_bib44","first-page":"H848","article-title":"Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy","volume":"277","author":"Anumba","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib45","first-page":"R847","article-title":"Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats","volume":"257","author":"Conrad","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/01.HYP.31.5.1065","article-title":"Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats","volume":"31","author":"Khalil","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib47","doi-asserted-by":"crossref","first-page":"R1390","DOI":"10.1152\/ajpregu.2001.281.5.R1390","article-title":"Role of neuronal nitric oxide synthase in mediating renal hemodynamic changes during pregnancy","volume":"281","author":"Abram","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib48","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/0002-9378(95)90328-3","article-title":"Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia","volume":"173","author":"Lyall","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.HYP.35.1.367","article-title":"Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat","volume":"35","author":"Crews","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1172\/JCI118059","article-title":"Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats","volume":"96","author":"Danielson","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.09.023_bib51","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/S0002-9378(13)90488-9","article-title":"Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation","volume":"170","author":"Molnar","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ajog.2005.05.054","article-title":"Expression of phosphodiesterase 5 in maternal and fetal sheep","volume":"193","author":"Coppage","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10641950802601278","article-title":"A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia","volume":"28","author":"Samangaya","year":"2009","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.clinthera.2014.09.023_bib54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/10641951003634766","article-title":"Sildenafil for the treatment of preeclampsia","volume":"29","author":"Downing","year":"2010","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.clinthera.2014.09.023_bib55","doi-asserted-by":"crossref","first-page":"R397","DOI":"10.1152\/ajpregu.00216.2013","article-title":"Sildenafil attenuates placental ischemia-induced hypertension","volume":"305","author":"George","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib56","doi-asserted-by":"crossref","first-page":"F810","DOI":"10.1152\/ajprenal.00117.2010","article-title":"Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat","volume":"299","author":"Sasser","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2014.09.023_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/01.HYP.37.2.485","article-title":"Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure","volume":"37","author":"Alexander","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.HYP.0000197950.42301.dd","article-title":"Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion","volume":"47","author":"Roberts","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.09.023_bib59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1242\/dev.125.5.813","article-title":"Cranial and cardiac neural crest defects in endothelin-a receptor-deficient mice","volume":"125","author":"Clouthier","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.clinthera.2014.09.023_bib60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.lfs.2003.09.027","article-title":"Pharmacological knockout of endothelin et(a) receptors","volume":"74","author":"Taniguchi","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2014.09.023_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/107155760100800103","article-title":"Differential effects of endothelin A and B receptor antagonism on fetal growth in normal and nitric oxide-deficient rats","volume":"8","author":"Thaete","year":"2001","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.clinthera.2014.09.023_bib62","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0006-291X(92)91710-8","article-title":"The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta","volume":"185","author":"Webb","year":"1992","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:32Z","timestamp":1758962972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814006158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0149291814006158"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Approaches for Managing Preeclampsia: Clues From Clinical and Basic Research","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}